Neuren Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Neuren Pharmaceuticals is Jon Pilcher, benoemd in May2020, heeft een ambtstermijn van 4.5 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.36M, bestaande uit 40.2% salaris en 59.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.31% van de aandelen van het bedrijf, ter waarde A$ 5.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 6.3 jaar.

Belangrijke informatie

Jon Pilcher

Algemeen directeur

AU$1.4m

Totale compensatie

Percentage CEO-salaris	40.2%
Dienstverband CEO	4.5yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	4.4yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04

Analyse CEO-vergoeding

Hoe is Jon Pilcher's beloning veranderd ten opzichte van Neuren Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	AU$117m
Mar 31 2024	n/a	n/a	AU$137m
Dec 31 2023	AU$1m	AU$549k	AU$157m
Sep 30 2023	n/a	n/a	AU$106m
Jun 30 2023	n/a	n/a	AU$55m
Mar 31 2023	n/a	n/a	AU$28m
Dec 31 2022	AU$546k	AU$396k	AU$184k
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	n/a	n/a	-AU$7m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	AU$432k	AU$203k	-AU$8m

Compensatie versus markt: De totale vergoeding ($USD 887.13K ) Jon } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 1.10M ).

Compensatie versus inkomsten: De vergoeding van Jon is het afgelopen jaar met meer dan 20% gestegen.

CEO

Jon Pilcher

4.5yrs

Tenure

AU$1,364,404

Compensatie

Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Pilcher	CEO, MD & Executive Director	4.5yrs	AU$1.36m	0.31% A$ 5.5m
Lauren Frazer	CFO & Company Secretary	4.3yrs	geen gegevens	geen gegevens
Lawrence Glass	Chief Science Officer	20.8yrs	geen gegevens	geen gegevens
Gerry Zhao	Vice President of Corporate Development	no data	geen gegevens	geen gegevens
Liza Squires	Chief Medical Officer	2.3yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van NEU wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Pilcher	CEO, MD & Executive Director	3.4yrs	AU$1.36m	0.31% A$ 5.5m
Dianne Angus	Independent Non-Executive Director	6.3yrs	AU$75.00k	0.023% A$ 410.7k
Jenny Harry	Independent Non-Executive Director	6.3yrs	AU$75.00k	0.023% A$ 406.1k
Patrick Donald Davies	Independent Non-Executive Chairman	6.3yrs	AU$125.00k	0.21% A$ 3.6m
Joe Basile	Independent Non-Executive Director	1.7yrs	AU$62.50k	0.017% A$ 293.1k

6.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van NEU wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Neuren Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Independent Non-Executive Director recently bought AU$59k worth of stock

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Recent updates

Now 24% undervalued

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 17%, EPS downgraded

New major risk - Revenue and earnings growth

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

First half 2024 earnings: EPS misses analyst expectations

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Price target decreased by 7.5% to AU$26.54

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 15%

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Price target increased by 7.9% to AU$28.19

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Price target increased by 27% to AU$24.22

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Price target increased by 18% to AU$19.14

Now 20% undervalued after recent price drop

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Now 25% undervalued after recent price drop

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Consensus EPS estimates fall by 12%

Price target increased by 8.3% to AU$15.07

Independent Non-Executive Director recently sold AU$15m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 18% to AU$10.60

Consensus EPS estimates fall by 14%

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Price target increased by 12% to AU$8.99

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Price target increased to AU$7.83

Price target increased to AU$7.83

Price target increased to AU$7.37

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Consensus estimates of losses per share improve by 47%

Price target increased to AU$6.62

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Consensus forecasts updated

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome